ZA200907280B - Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance - Google Patents

Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance

Info

Publication number
ZA200907280B
ZA200907280B ZA200907280A ZA200907280A ZA200907280B ZA 200907280 B ZA200907280 B ZA 200907280B ZA 200907280 A ZA200907280 A ZA 200907280A ZA 200907280 A ZA200907280 A ZA 200907280A ZA 200907280 B ZA200907280 B ZA 200907280B
Authority
ZA
South Africa
Prior art keywords
complications
diabetes
prevention
type
insulin resistance
Prior art date
Application number
ZA200907280A
Inventor
Claudio Cavazza
Paolo Carminati
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ZA200907280B publication Critical patent/ZA200907280B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200907280A 2007-03-21 2009-10-19 Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance ZA200907280B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07104624 2007-03-21

Publications (1)

Publication Number Publication Date
ZA200907280B true ZA200907280B (en) 2010-06-30

Family

ID=38328657

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200907280A ZA200907280B (en) 2007-03-21 2009-10-19 Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance

Country Status (25)

Country Link
US (1) US8389574B2 (en)
EP (1) EP2136798B1 (en)
JP (2) JP5982091B2 (en)
KR (1) KR20090120503A (en)
CN (1) CN101663030B (en)
AU (1) AU2008228192B2 (en)
BR (1) BRPI0809034A8 (en)
CA (1) CA2681185C (en)
CY (1) CY1116872T1 (en)
DK (1) DK2136798T3 (en)
EA (1) EA018442B1 (en)
ES (1) ES2546619T3 (en)
HK (1) HK1139040A1 (en)
HR (1) HRP20150936T1 (en)
HU (1) HUE025394T2 (en)
IL (1) IL201014A (en)
MX (1) MX2009009966A (en)
MY (1) MY151623A (en)
NZ (1) NZ579767A (en)
PL (1) PL2136798T3 (en)
PT (1) PT2136798E (en)
SG (2) SG10201507488RA (en)
SI (1) SI2136798T1 (en)
WO (1) WO2008113862A2 (en)
ZA (1) ZA200907280B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8589106B2 (en) * 2010-12-22 2013-11-19 Roche Diagnostics Operations, Inc. Calibration of a handheld diabetes managing device that receives data from a continuous glucose monitor
KR20190043076A (en) * 2017-10-17 2019-04-25 한미약품 주식회사 Pharmaceutical composition comprising amlodipine, losartan and rosuvastatin for prevention and treatment of cardiovascular diseases accompanied by diabetes and formulated combination including the same
CN115068451A (en) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 Medical application of hypocrellin compound as LTB4 receptor inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (en) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4- (2'-nitrophenyl) -2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine
IT1254314B (en) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ACYL-CARNITINE ASSOCIATION WITH ACE-INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
IT1263004B (en) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti USE OF L-CARNITINE AND ACIL L-CARNITINE IN THE LONG-TERM TREATMENT OF NON-INSULIN-EMPLOYEE DIABETIC PATIENTS.
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IT1290801B1 (en) * 1996-07-05 1998-12-11 Mendes Srl USE OF ACETYL L-CARNITINE, ISOVALERYL L-CARNITINE, PROPIONYL L-CARNITINE OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS
IT1293067B1 (en) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PATHOLOGIES CAUSED BY ALTERED LIPID METABOLISM
IT1291113B1 (en) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti NUTRITIONAL THERAPEUTIC COMPOSITION FOR SUBJECTS WITH DIABETES MELLITUS
US6281234B1 (en) * 1998-05-12 2001-08-28 American Home Products Corporation (2-Acylaminothiazole-4-yl)acetic acid derivative
IT1302289B1 (en) * 1998-09-30 2000-09-05 Univ Catania PHARMACEUTICAL COMPOSITIONS WITH ANTINEOPLASTIC ACTIVITY
WO2000074675A1 (en) * 1999-06-08 2000-12-14 Sigma-Tau Industrie Farmaceutiche S.P.A. Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
ITRM20010294A1 (en) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti USE OF ACETYL L-CARNETINE IN ASSOCIATION WITH BIOTIN FOR THE TREATMENT OF PATIENTS WITH DIABETES TYPE II INSULIN RE
US20030068391A1 (en) * 2001-10-04 2003-04-10 Harris Dennis H. Ingestible nerve and circulatory nutritional formulation

Also Published As

Publication number Publication date
JP5974056B2 (en) 2016-08-23
HK1139040A1 (en) 2010-09-10
EA018442B1 (en) 2013-08-30
MX2009009966A (en) 2009-10-07
KR20090120503A (en) 2009-11-24
HRP20150936T1 (en) 2015-09-25
IL201014A0 (en) 2010-05-17
JP2014237717A (en) 2014-12-18
AU2008228192B2 (en) 2013-02-07
CY1116872T1 (en) 2017-04-05
CA2681185A1 (en) 2008-09-25
SI2136798T1 (en) 2015-10-30
SG10201507488RA (en) 2015-10-29
WO2008113862A3 (en) 2008-12-31
CN101663030B (en) 2013-08-21
WO2008113862A2 (en) 2008-09-25
DK2136798T3 (en) 2015-08-31
EP2136798B1 (en) 2015-07-29
JP2010521536A (en) 2010-06-24
SG193655A1 (en) 2013-10-30
CN101663030A (en) 2010-03-03
MY151623A (en) 2014-06-30
CA2681185C (en) 2018-05-01
PL2136798T3 (en) 2015-11-30
BRPI0809034A8 (en) 2017-12-26
ES2546619T3 (en) 2015-09-25
IL201014A (en) 2017-06-29
NZ579767A (en) 2012-04-27
AU2008228192A1 (en) 2008-09-25
BRPI0809034A2 (en) 2014-10-07
PT2136798E (en) 2015-10-15
EA200970877A1 (en) 2010-04-30
HUE025394T2 (en) 2016-02-29
US20100048691A1 (en) 2010-02-25
US8389574B2 (en) 2013-03-05
EP2136798A2 (en) 2009-12-30
JP5982091B2 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
IL215925A0 (en) Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus
EP2201370A4 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
IL195947A (en) Fused cyclic compounds and pharmaceutical compositions comprising them for use in the prevention and treatment of diabetes
EP2022495A4 (en) Composition for preventing the occurrence of cardiovascular event in multiple risk patient
IL184312A0 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
EP2307544A4 (en) Genetic component of complications in type 2 diabetes
ZA201007114B (en) Compositions useful for the treatment of diabetes and other chronic disorder
EP2069768A4 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
EP2199295A4 (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
ZA201000990B (en) Herbal formulations for controlling blood glucose levels in patients with diabetes
EP2298365A4 (en) Medical composition and medical kit
IL208463A (en) 2-heterocyclyl-fused pyrrole compounds, pharmaceutical compositions comprising them and their use in the prophylaxis or treatment of diabetes or obesity
IL177609A (en) Use of gabaculine or its analog in the manufacture of a medicament for treating hepatocellular carcinoma
EP2010164A4 (en) S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
PL2012805T3 (en) Therapeutic composition and use
ZA200904583B (en) Dual composition with warming and analgesic effects
PL2308497T3 (en) Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers
ZA200907280B (en) Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
IL207647A0 (en) Use of interleukin-1 conjugates in the treatment of diabetes
PL2217255T3 (en) Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome
HK1130177A1 (en) A pharmaceutical composition for treating type ii diabetes and complications thereof
PL2250179T3 (en) Lecithin based composition and its use in food
EP2189163A4 (en) A composition for treatment of diabetes mellitus and a preparation and an use thereof
HK1147700A1 (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including man
EP2275437A4 (en) Polypeptide and pharmaceutical composition containing the polypeptide